Sponsor: Hoosier Oncology Group - HOG
Sponsor Study ID: HCRN BRE20-468
Study Title: A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer
CTO #: 103624
NCT Number: NCT05467891
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To estimate subsequent recurrence-free survival at 3 years for ribociclib when administered with ET in patients who hormone receptor positive, HER2 negative breast cancer with adequately resected local recurrence of early breast cancer.